1.03
-6.36%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Synlogic
From its filings with the US Securities and Exchange Commission
Synlogic is based in Winchester, Massachusetts and is incorporated in Delaware. Its shares trade on OTC under the ticker SYBX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $1.0m. At that date it held total assets of $15.4m and shareholders' equity of $11.9m.
We are a biopharmaceutical company that previously advanced novel therapeutics to transform the care of serious diseases. We focused on rare metabolic disorders, with our lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). Both PKU and HCU are caused by inborn errors of metabolism, and present significant need for innovation due to limitations of both efficacy and safety in the currently available medical treatment options. In February 2024, we made the decision to discontinue Synpheny-3, our pivotal study of our lead product candidate, labafenogene marselecobac (SYNB1934), as a potential treatment for PKU. The decision to end Synpheny-3 is based on results of an internal review in advance of an upcoming independent Data Monitoring Committee (DMC) assessment, which indicated the trial was unlikely to meet its primary endpoint. The decision was not based on concerns regarding safety or tolerability. As a result, our current corporate strategy is focused on pursuing strategic initiatives to enhance stockholder value, including but not limited to, a merger or the sale of the Company. Our strategic process is both active and ongoing and includes a range of interactions with transaction counterparties. Thus, we believe it is in our stockholders’ best interest to allow sufficient opportunity to pursue and consummate one or more such transactions and to consider additional alternatives that may materialize in the future.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Sept 2015
- Employees
- 1
- Website
- synlogictx.com ↗
- Head office
- PO BOX 30, WINCHESTER, MA, 01890
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Peter BarrettIndependent Chairman of the Board$81,500
- Ms. Mary DooleyPrincipal Executive Officer, Principal Financial Officer$486,490
- Mr. James FlynnIndependent Director$36,721
- Mr. Edward MathersIndependent Director$45,000
- Mr. Richard SheaIndependent Director$55,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 66
- Social
- 75
- Governance
- 47
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Synlogic's proprietary Synthetic Biotic platform enables targeted treatment of rare genetic diseases like UCD and PKU.
- Synlogic's pipeline includes SYNB1020 for Urea Cycle Disorder and SYNB1618 for Phenylketonuria.
- Synlogic focuses on innovative synthetic biology applications in the Health Care sector.
Weaknesses
- Synlogic employs only 76 full-time employees, which may limit operational capacity.
- Synlogic's IPO was in 2015, indicating a relatively young company with limited market history.
- Synlogic's clinical-stage development requires significant future funding for pipeline advancement.
Opportunities
- Synlogic's Synthetic Biotic medicines address inflammatory bowel disease, cancer, and metabolic conditions like diabetes.
- Synlogic's focus on inborn errors of metabolism (IEM) opens new therapeutic markets.
- Synlogic's platform can expand into additional rare genetic disease treatments.
Threats
- Synlogic's clinical-stage status poses risks of development failures in pipeline products.
- Synlogic faces competition from other biotech firms in the Health Care sector.
- Synlogic's reliance on synthetic biology may encounter regulatory hurdles in drug approval.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.